Two early career researchers (ECRs) from the Monash Biomedicine Discovery Institute (BDI) have received Fellowships from the Australian Society for Biochemistry and Molecular Biology (ASBMB), in recognition of their outstanding work in their field.
Congratulations to Dr Gabby Watson from the Rossjohn lab and Dr Chris Stubenrauch from the Lithgow lab.
Dr Gabby Watson’s postgraduate research utilised structural biology to design and characterise cyclic peptides targeted to an intracellular breast cancer protein, Grb7. This resulted in six publications, many as first-author, including two in the Journal of Medicinal Chemistry.
She is currently investigating the complexities and specificities of ligand recognition by the inhibitory receptor CD96, an emerging target for cancer immunotherapy, with some of this research recently published in Structure.
This ASBMB Fellowship will enable Dr Watson to travel to Vienna, Austria, to present her latest research at the 32nd European Crystallographic Meeting.
“I am honoured to receive an ASBMB Fellowship, and grateful to have the opportunity to discuss our recent discoveries on CD96 ligand recognition with experts in the European crystallographic community,” Dr Watson said.